Daunorubicin/cytarabine

Daunorubicin/cytarabine, sold under the brand name Vyxeos, is a fixed-dose combination medication used for the treatment of acute myeloid leukemia.^[3][5] It contains the liposomal bound daunorubicin, an anthracycline topoisomerase inhibitor, and cytarabine, a nucleoside metabolic inhibitor.^[3]

Daunorubicin/cytarabine

Cytarabine
Daunorubicin
Combination of
Daunorubicin	Anthracycline
Cytarabine	Antimetabolite
Clinical data
Trade names	Vyxeos
Other names	CPX-351
AHFS/Drugs.com	Monograph
License data	US DailyMed: Vyxeos
Pregnancy category	AU: D[1]
Routes of administration	Intravenous
ATC code	L01XY01 (WHO)
Legal status
Legal status	AU: S4 (Prescription only)[1] CA: ℞-only[2] US: ℞-only[3] EU: Rx-only[4]
Identifiers
CAS Number	1256639-86-7
KEGG	D11390

Medical uses

Daunorubicin/cytarabine is indicated for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in people aged one year of age and older.^{[3][6][7][8][9]}